|UMMS Research News|
|Calendars at Health System Headlines|
|Research Seminars and Events|
FEBRUARY 2013, Vol. 31
The Strategic Research Initiative was launched in June 2012, and over the last six months 10 scientific concept groups, involving hundreds of faculty, have worked diligently to assemble teams, refine scientific theses, and draft proposals to “fast forward to tomorrow’s cures.” Six have been selected to move forward by the Research Board of Directors, including:
- Chemical Biology and Drug Discovery Initiative in Epigenetics
- Cure Obesity
- Discovery of New Diseases: A Comprehensive Rare Disease Research Program
- Personalized Medicine
- Host-Microbiome Initiative
- Center for Protein Folding Diseases
Last week a panel of external experts met to review these proposals and make their recommendations for funding to the Research Board of Directors. Notification of final awards is expected to occur in late April, and the Office of Research will celebrate the announcement and launch of the programs with U-M colleagues and the general public at a “Fast Forward Forum” event in May.
The Office of Research has made great strides on other “fast forward” strategies that have continued in parallel with the scientific proposals. Despite a challenging financial climate, Medical School leadership continues to fully support infrastructure investments that benefit our entire research community, with the latest developments including:
- New assets for the Biomedical Research Core Facilities.
- New Honest Broker Office to help investigators gain access to clinical data.
- Work has begun to establish a federated research data warehouse.
- Work started and endorsement from the Research Board of Directors to create a centralized biorepository system.
- Improved regulatory processes, including restructuring IRBMED.
- Streamlined execution for industry-sponsored trials.
- Integration of clinical research with MiChart.
- New Mentored Research Academy and its "R01 Boot Camp."
The benefits of these investments reach far beyond the walls of the Medical School, benefiting the broader university research enterprise and ultimately impacting patients. You can learn more about all of the initiatives, including reading the executive summaries of the six scientific proposals, at the Strategic Research Initiative website.
The 2nd annual BRCF Technology & Services Showcase will bring together dozens of vendors along with our own Cores to exhibit the latest technology and service innovations available to biomedical researchers.
The Proteomics & Peptide Synthesis Core, Flow Cytometry Core, Metabolomics Core, DNA Sequencing Core and Bioinformatics Core will demonstrate sample preparations, host prominent thought leaders in their fields and hold Q&A sessions. Visit the website for full details on the speaking sessions.
Tuesday, March 19, 2013
10:00 AM – Speaking Sessions Begin
11:30 AM - 2:30 PM – Exhibitors Open
Palmer Commons, Great Lakes Room (4th Floor)
For more information, visit the BRCF website. Sponsored by the Biomedical Research Core Facilities and Biotech Vendor Services, Inc.
In FY 2012, the successful funding rate for first-time R01-type submissions to the NIH was close to 20% for established investigators, while it was less than 15% for first-time applicants. With that in mind, the Medical School Office of Research, with support of Dean Woolliscroft, recently launched a pilot version of the Mentored Research Academy and its “R01 Boot Camp.”
Over the course of the next year, 40 investigators who have yet to receive an R01 grant from the NIH will be mentored by senior faculty and coached through a process of close internal review in preparing a grant application. Representing 26 different departments including basic, translational, and clinical research, each faculty participant will be expected to submit an R01 application by February 2014. Over the course of the year, they’ll benefit from working with their peers and senior mentors on collaborative, interdisciplinary teams and networking with scientific experts here at the University and beyond. Success rates of these and related grant applications will be monitored over the course of the next few years.
Part of the Strategic Research Initiative’s investment in activities across the research spectrum, the R01 Boot Camp underscores the Medical School’s commitment to seeing ALL faulty become nationally recognized leaders in their fields. “Competition for grant funding has never been more challenging than it is today,” notes one of the senior faculty coaches, David Aronoff, M.D. “The R01 Boot Camp is the strongest attempt I have seen of teaching the art of grant writing to the next generation of independently-funded investigators. It sets a new standard for how academic institutions support and accelerate the independent careers of their young investigators.”
For questions about the R01 Boot Camp, please contact Chris Black at R01BootCamp@umich.edu.
As one of many infrastructure investments that are part of the Strategic Research Initiative, the Medical School Office of Research recently opened the Honest Broker Office (HBO). The HBO has been established to help faculty “fast forward” access to clinical data for research and is IRBMED approved.
Now any Medical School investigator who requires a clinical data set or an aggregate count for cohort feasibility can simply go to the HBO website and submit a request form online. “In such a decentralized environment, fast and secure access to clinical data has always been a challenge for Med School faculty,” notes the new office’s director, Deb Gipson, M.D. “Our HBO team can now step in to facilitate, freeing researchers to focus more on science and less on process.”
To learn more about the Honest Broker Office or to submit a data request, visit the HBO website.
Last fall the University launched MCubed, a research funding program that lets faculty themselves decide which projects to pursue. A formal, external review isn't part of the process. To qualify for "cube" funding, three researchers from at least two disciplines simply have to agree to work together on a new project.
In early December, 50 projects “cubed” and were slated to receive $60,000 seed grants in phase one of the program, with 50 faculty from the Medical School collaborating. The two-year pilot, comprised of $15 million from the U-M Provost and participating schools, colleges, and units, will ultimately distribute 200 more early-stage grants, in an effort to jumpstart innovative and interdisciplinary collaboration. The Medical School is contributing $1 million to the program.
The second cubing phase closed in late December and once again stimulated a wide array of projects that attest to the creativity and talent of U-M Medical School faculty and their colleagues across campus. This phase resulted in funding for 117 cubes, with over 100 Medical School investigators involved.
Many projects address the latest hot-button issues in health research. For instance, one cube involving John Piette of Internal Medicine will study mobile apps and the use of automated and data-driven reinforcement learning to make health communications adaptive to the patient's experience and conditions. Another project involving Jun Hun Lee of Molecular and Integrative Physiology and Robert Wessells of Internal Medicine will explore whether Sestrins can mimic exercise and thus extend lifespan. Key themes across the 117 newly funded cubes include cancer therapy, big data, and the human-machine interface.
For more details about these cubes and others, or about the next cubing phase which begins February 27, go to the MCubed website.
This newsletter published by the MBECT Team provides regular correspondence about things like major system upgrades and frequently asked questions as well as a few tips and timesaving tricks. Here are links to the latest issues:
As always, the MBECT Team is interested in any feedback or questions you may have. You can contact the help desk at MBECTHelp@umich.edu or 734-764-KNOW (5669).
NOTE: Links marked with a key are designated as “University Access - Ann Arbor Campus Only” and can only be accessed if you are on the University of Michigan Ann Arbor Campus network or if you are logged in via a VPN (Virtual Private Network).
SEMINARS + MAJOR EVENTS AND CONFERENCES
Visit the calendars at Health System Headlines to make sure you're "in the loop" with current events!
There are two ways to find upcoming seminars throughout campus on basic, clinical and translational research:
- "Research Seminars and Events" calendar.
- "Research Seminars and Events" announcement category – Suscribe to the RSS feed for this category to receive emails containing complete articles.
RESEARCH COMPLIANCE TRAINING AND EDUCATION
To All Faculty Performing Biological Research at University of Michigan – Important Federal Changes:
Synthetic Nucleic Acid Molecules Added to the NIH Guidelines for Research Involving Recombinant DNA Molecules, effective March 2013
The NIH Office of Biotechnology Activities (NIH OBA) has amended the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) to include research with synthetic nucleic acid molecules, and such work must be registered with the UM Institutional Biosafety Committee by March 5, 2013.
The amended NIH Guidelines, at Section I-B, define recombinant and synthetic DNA molecules as:
(i) molecules that:
a) are constructed by joining nucleic acid molecules and
b) that can replicate in a living cell, i.e., recombinant nucleic acids;
(ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, i.e., synthetic nucleic acids, or
(iii) molecules that result from the replication of those described in (i) or (ii) above.
Please note that small DNA molecules such as oligonucleotides and PCR primers are not included in these categories.
Below is further information on how this applies to laboratory (bench) research and clinical research. The final section below notes how the federal regulations governing select agent research have also been updated to include reference to synthetic nucleic acids and synthetic organisms.
Laboratory research that meets any one of the criteria below must be registered with the IBC. To do so, please go to http://www.eresearch.umich.edu to newly register or amend your current IBC registration to describe your research with synthetic nucleic acid molecules in Section 3. Email us at IBCSyntheticDNA@umich.edu with questions.
Criteria requiring registration:
- The synthetic nucleic acid molecules you are working with can replicate.
- They can generate nucleic acids that can replicate in a living cell.
- They can integrate into a host cell’s DNA.
- They produce a toxin that is lethal for vertebrates at an LD50 of less than 100 nanograms/kilogram body weight.
- They synthesize an organism that doesn’t naturally occur outside of a laboratory setting (i.e., 1918 H1N1 influenza, wild-type polio virus).
The definition in the NIH Guidelines of human gene transfer has been amended (Section III-C-1). If you have clinical research that meets any one of the criteria below, please go to http://www.eresearch.umich.edu and amend your IRB protocol to indicate human gene transfer (you will then complete Section 23 of the IRB application). Email us at IBCSyntheticDNA@umich.edu with questions.
Human gene transfer is now defined as the deliberate transfer into human research participants of either:
- Recombinant nucleic acid molecules, or DNA or RNA derived from recombinant nucleic acid molecules, or
- Synthetic nucleic acid molecules, or DNA or RNA derived from synthetic nucleic acid molecules, that meet any one of the following criteria:
- Contains more than 100 nucleotides; or
- Possesses biological properties that enable integration into the genome (e.g., cis elements involved in integration); or
- Have the potential to replicate in a cell; or
- Can be translated or transcribed.
Select Agent Regulations Modified pertaining to Synthetic Nucleic Acids and Synthetic Organisms
The federal regulations governing research with Select Agents (42 CFR 73) have likewise been modified pertaining to synthetic nucleic acids and synthetic organisms, at Sections 73.3(c) and 73.4(c):
42 CFR 73 Sections [73.3(c)] and [73.4(c)]:
Genetic Elements, Recombinant and/or Synthetic Nucleic Acids, and Recombinant and/or Synthetic Organisms:
- Nucleic acids that can produce infectious forms of any of the select agent viruses listed at [73.3(b)], or the overlap select agent viruses listed at [73.4(b)].
- Recombinant and/or Synthetic nucleic acids that encode for the functional form(s) of any of the toxins listed at [73.3(b)] or [73.4(b)] if the nucleic acids:
(i) Can be expressed in vivo or in vitro, or
(ii) Are in a vector or recombinant host genome and can be expressed in vivo or in vitro.
- Select agents and toxins listed at [73.3(b)] or [73.4(b)] that have been genetically modified.
If you are planning any work that involves select agents or toxins, please contact the university’s Responsible Official (Janet Follo, 734-647-3133, email@example.com) to initiate the review and approval process for the work.
The Michigan Institute for Clinical & Health Research (MICHR) is pleased to present “Start Here: Navigating the Regulatory Environment at U-M,” a workshop for faculty and postdoctoral fellows who are new to the University of Michigan or new to clinical and translational research.
There are two parts to this “blended learning” offering. Six 8-12 minute introductory modules have been developed for viewing online. Topics of the online modules include good clinical practice, disclosure and conflict of interest, working with ORSP, IRB, and clinical research billing.
After viewing all six, participants may attend an optional 1.5 hour discussion to learn more about research resources available from MICHR or to ask specific questions, which will be answered by regulatory experts.
This workshop is free, but registration is required. Registration closes March 8, 2013. View full details and register.
Please note that this workshop is intended for faculty and fellows only. If you are a U-M staff member looking for an introduction to clinical research at U-M, please see the Basics of Clinical Research series.
You may need an outgoing Material Transfer Agreements (MTA) from the Office of Technology Transfer!
MTAs describe the terms under which University researchers can share materials, typically for research or evaluation purposes. Intellectual property rights can be endangered if materials are used without a proper MTA. For the most up to date information, please see our website.
UM requires contacting Tech Transfer for an outgoing MTA if the material is:
- Human-derived tissues, fluids, or samples of any kind or will be used with human subjects.
- A regulated substance containing pathogens or other harmful biological agents.
- Technology described in, or is part of, an Invention Report that UM is protecting or has protected under one or more patents or pending patents.
- Intellectual property exclusively licensed by UM to another party.
- Was received from another party under an agreement (e.g., other MTAs, sponsored research agreements, or commercial purchases with use limitations).
- Being transferred outside of the United States.
- Being transferred to a recipient NOT at a non-profit/research institution.
Aren’t sure? Just drop Tech Transfer an email or a phone call to check in!
Keep in mind that an MTA is useful even when not required in order to allow limitations on additional transfers of the material by the recipient, protecting the ownership of the material, ensuring an exchange for materials or publication review, and limiting the use of the material.
*Remember, Tech Transfer needs to be the authorized signature on the agreement, not the faculty member!
Please feel free to contact Tech Transfer to discuss any questions and to provide the appropriate information for the outgoing MTA: Katie Moynihan (734-763-0441 or firstname.lastname@example.org).
SHARPENING THE FOCUS:
Tips on Grant Proposal Preparation
By Chris Black, M.L.S., Assistant Director for Research Services, Office of Research
(This is one in a series of tips published in UMMS Research News about writing proposals.)
LikeThis is a new search tool to aid NIH Principal Investigators in finding and learning about other research projects that have similar goals and objectives as their own. By entering specific scientific terms or accessing their own grant applications or grants and clicking on LikeThis, investigators will be provided a listing of similar funded projects and/or publications.
With the ability to find similar projects and publications, PIs can more quickly and efficiently:
- find out new ideas for research based on what NIH has awarded in the past;
- see what NIH is doing in his or her area of interest;
- use the information as a decision tool to determine if they need to come up with a fresh research idea; and
- figure out in which study section his or her application should be reviewed.
LikeThis is available from the eRA Commons home page under the “Additional Links” section along the right side of the page. Go to the NIH Electronic Research Administration (eRA) LikeThis webpage to explore.
Thursday, February 21, 2013
9:30 - 11:00 AM
Learning Resource Center, Medical School, 3950 Medical Sciences Building II
Sponsored by Taubman Health Sciences Libraries.
This workshop offers instruction on the efficient and proper placement of images, charts, and graphics into grant proposal applications. The session will cover basic features in Microsoft Word such as image placement, captioning, and text wrapping. Following a brief presentation and hands-on instruction, instructors will assist you with specific issues you’re encountering in formatting your grant application. The session will cover all versions of Microsoft Word and applies to placement of graphics into any Word document. Please feel free to bring sample documents!
Contact Merle Rosenzweig with any questions. You can also view a video of this workshop and related documentation online.
The Michigan Institute for Clinical & Health Research (MICHR) is pleased to announce that the 2013 Research Education Symposium, "Life at the Interface of Genomics and Clinical Care," will take place on Friday, March 15, 2013. The event includes a morning poster session, the announcement of the 2013 MICHR Distinguished Clinical and Translational Research Mentor Award recipients, and a symposium featuring several U-M faculty.
The keynote speaker, Dr. Ellen Wright Clayton, J.D., M.D., will address biomedical ethics. Dr. Wright Clayton is an internationally respected leader in the field of law and genetics who holds appointments in both the law and medical schools at Vanderbilt, where she also co-founded the Center for Biomedical Ethics and Society.
Thursday, March 21, 2013
9:30 - 11:00 AM
Taubman Learning Center, 2802 Medical Sciences Building II
Sponsored by Taubman Health Sciences Libraries.
By default, EndNote creates a single bibliography at the end of each of your Word documents. However, you may want to create a separate bibliography for each section of your dissertation or at the end of each chapter in your document. This hands-on workshop will show you how to do this.
The Center for Bioethics and Social Sciences in Medicine (CBSSM) Research Colloquium will take place on April 17, 2013, 8:30 AM - 4:30 PM, in the Founders Room, Alumni Center (200 Fletcher Street, Ann Arbor, MI 48109). The Colloquium features presentations focusing on bioethics and social sciences in medicine across multiple disciplines.
The keynote address is the Bishop Lecture in Bioethics, an endowed lectureship made possible by a gift from the estate of Ronald C. and Nancy V. Bishop. Ruth Macklin, Ph.D., Professor of Epidemiology & Population Health and Dr. Shoshanah Trachtenberg Frackman Faculty Scholar in Biomedical Ethics at the Albert Einstein College of Medicine, will present the Bishop Lecture with a talk entitled, “Global Gender Justice: Violence Against Women; Whose Responsibility?”
Keynote Abstract: In some countries, governmental authorities have done little to prevent or punish violence against women. Examples of gender-based violence include not only intimate partner violence, but also rape as a weapon of war, civilian rape, and killing condoned in so-called "honor cultures." Can a theory of global justice shed light on whether external governments or non-governmental groups should take responsibility for remedying the situation? Who has the responsibility to respond to human rights violations?
The Bishop Lecture in Bioethics will be jointly presented by the Bishop Lectureship in Bioethics fund and by the Center for Bioethics and Social Sciences in Medicine (CBSSM).
Registration will begin mid-March.
Abstracts are welcome from all disciplines and institutions. The deadline for submission is March 15, 2013. Download the abstract submission form.
FUNDING / AWARD OPPORTUNITIES
Abstracts listed here are general information about these funding programs. We strongly urge interested applicants to visit the listed website to verify complete eligibility, program information, and application procedures before submitting an application.
Follow this link to search for other funding and recognition opportunities. This webpage contains information on email alert groups, internal grant programs, upcoming limited submissions, and links to extramural funding search engines.
Deadline: March 18. 2013
The Postdoctoral Translational Scholars Program is a multidisciplinary career development program supported by the Michigan Institute for Clinical & Health Research (MICHR) that is designed to prepare individuals with a Ph.D. in a biomedical science or social science discipline for independent careers in translational research.
Individuals with PhD degrees who are interested in obtaining additional training in translational sciences are encouraged to apply for this unique funding opportunity that will provide trainees with a $100,000 career development award to be used over two to three years. Award funding can be used to support the individual’s salary, course work, and/or research activities. Postdoctoral Translational Scholars will be expected to commit 50 to 75 percent of full time effort to the program. You must be a U.S. citizen or U.S. permanent resident to apply.
For more information and to apply, visit the website.
Deadline: March 30, 2013 (5:00 PM)
The University of Michigan Health System (UMHS) and the Peking University Health Science Center (PUHSC) Joint Institute for Translational and Clinical Research (http://www.puuma.org/) is accepting joint proposals from investigators working collaboratively at both institutions for pilot funding of projects that will demonstrate an effective team approach to discovery and new findings on diseases relative to both countries, and which can be leveraged for extramural funding opportunities.
Both UMHS and PUHSC have made significant commitments to supporting scientists to translate scientific discoveries into real health gains more quickly and efficiently, and to promote the development of novel solutions that will ultimately improve health outcomes in the US, in China, and around the world. In the initial phase of the Joint Institute (JI), three programs – pulmonary, cardiovascular, and liver – were identified because of their overall importance to global health, as well as the opportunity for effective collaboration and the potential for translational impacts. While these programs remain major research foci areas for the JI, the Executive Board is extending the opportunity to become a part of the JI to scientists in other disciplines who seek to establish robust collaborations between the institutions that will lead to transformative science and that attracts extramural funding. New areas of interest include, but are not limited to: diabetes mellitus, renal disease, and cerebrovascular disease.
Proposals must include Co- Principal Investigators from both UMHS and PUHSC. Full-time research faculty and tenured and tenure-track instructional faculty are eligible to serve as Principal Investigators.
- Full Awards: up to $400,000/year* for two years (2-3 new awards anticipated)
- Discovery Awards: up to $100,000/year* for two years (4-6 new awards anticipated)
* Funding for all awards originate equally from UMHS and PUHSC with the intent that the respective amounts will be spent within the originating country.
External Open Submissions
Deadline: March 14, 2013 (Letters of Intent)
The Doris Duke Innovations in Clinical Research Award (ICRA) provides funding for early-stage research projects in clinical investigation to foster innovations in clinical research that advance the prevention, diagnosis and treatment of human disease.
The Doris Duke Charitable Foundation seeks proposals for cutting-edge clinical research that has the potential to catalyze innovative breakthroughs in sickle cell disease.
In keeping with the wishes expressed in Doris Duke's will, experiments that use animals or primary tissues derived from animals will not be supported by this program.
For complete competition details, visit the website.
UMMS AWARDED GRANTS
External Awarded Grants
An asterisk next to a name means that they are the Contact PI for the program, since some projects are awarded with multiple PIs.
Co-I: Tremper, Kevin (Anesthesiology Department)
Title: Identification of Indicators of Insufficient Neuromuscular Blockade in Patients Undergoing General Surgery
Sponsor: Merck Sharp & Dohme
Project Dates and Amount of Award: 01/31/13-12/31/13; $198,350
Comprehensive Cancer Center
Title: A Phase 1, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered BMN 673 in Patients with Advanced or Recurrent Solid Tumors
Sponsor: BioMarin Pharmaceutical Inc.
Project Dates and Amount of Award: 12/14/12-11/11/14; $218,238
Title: A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Advanced Malignancies Followed by an Expansion in Subjects with Measurable Disease
Sponsor: Intellikine, Inc
Project Dates and Amount of Award: 01/02/13-11/04/14; $252,645
Computational Medicine & Bioinformatics
PI: *Guan,Yuanfang / Burmeister,Margit
Title: Integrating Context-specific Networks to Predict Ataxia Genes
Sponsor: NIH 1 R21 NS 082212 01
Project Dates and Amount of Award: 03/01/13-02/28/15; $427,625
Title: AppyScore (TM) The Performance of the AppyScore (TM) Test in the Evaluation of Possible Acute Appendicitis in Children, Adolescents and Young Adults Presenting to the Emergency Department
Sponsor: Venaxis, Inc
Project Dates and Amount of Award: 01/24/13-12/31/13; $62,410
Awardee / Fellow: Cohen, Alicia
Title: Supplemental Nutrition Assistance Program (SNAP)
Sponsor: Fair Food Network
Project Dates and Amount of Award: 09/01/12-02/28/13; $40,000
Title: A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Sponsor: Bristol-Myers Squibb
Project Dates and Amount of Award: 01/15/13-01/14/17; $362,029
Title: Pragmatic Cluster Randomized Trail of an Asthma Intervention for Urban Teens.
Sponsor: NIH TO Henry Ford Health System R01 HL 114981
Project Dates and Amount of Award: 08/15/12-05/31/13; $78,557
Co-I: Chugh, Rashmi (Int Med-Hematology/Oncology)
Title: SARC Sarcoma Spore
Sponsor: NIH - Subcontracts TO SARC U54 CA 168512
Project Dates and Amount of Award: 09/26/12-08/31/13; $9,954
Title: Randomized, Double-blind, Placebo-controlled Phase 3 Study of PCI-32765, a Bruton's Tyrosine Kinase (Btk) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: Janssen Research and Development, LLC
Project Dates and Amount of Award: 01/04/13-10/31/17; $474,689
Co-I: Martens, Eric (Microbiology and Immunology) / Schloss, Patrick (Microbiology and Immunology) / Zhao, Lili (Biostatistics Department)
Title: Regulation of Intestinal Inflammation and Tumorigenesis by Nlrp6
Sponsor: NIH 1 R01 CA 166879 01 A1
Project Dates and Amount of Award: 01/18/13-12/31/17; $1,532,649
Co-I: Pop-Busui, Rodica (Metabolism, Endo & Diabetes)
Title: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D
Sponsor: NIH - Subcontracts TO Joslin Diabetes Center R34 DK 097808
Project Dates and Amount of Award: 09/25/12-08/31/13; $49,645
Title: Genes Determining Time to Onset of ESRD in T1D Patients with Proteinuria
Sponsor: Juvenile Diabetes Research Foundation International (JDRF) TO Joslin Diabetes Center
Project Dates and Amount of Award: 09/01/12-08/31/13; $58,542
Title: Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study
Sponsor: NIH - Subcontracts TO George Washington University U01 DK 098246
Project Dates and Amount of Award: 12/01/12-07/31/13; $30,694
Co-I: Pop-Busui, Rodica (Metabolism, Endo & Diabetes) / Tan, Meng (Metabolism, Endo & Diabetes)
Title: The Glycemia Reducation Approaches for Diabestes: A Comparative Effectiveness Study
Sponsor: NIH - Subcontracts TO George Washington University U01 DK 098246
Project Dates and Amount of Award: 01/01/13-07/31/13; $205,928
Title: EMD Serono Data Use Agreement Agreement for NCI Protocols 6735 and 6372
Sponsor: EMD Serono, Inc
Project Dates and Amount of Award: 01/18/13-11/01/13; $7,820
Title: Lupus and the Inflammasome
Sponsor: Alliance for Lupus Research
Project Dates and Amount of Award: 09/01/13-08/31/14; $190,111
Co-I: Schiopu, Elena (Int Med-Rheumatology)
Title: ACT12339: Double-Blind, Randomized, Placebo-Controlled, 8-week Study Investigating the Safety, Pharmacogenetics and Pharmacodynamics of SAR100842 Given Orally to Patients with Diffuse Cutaneous Systemic Sclerosis
Sponsor: Sanofi-Aventis Pharmaceuticals
Project Dates and Amount of Award: 11/19/12-03/31/14; $94,386
Co-I: Mclaughlin, Vallerie (Int Med-Cardiology)
Title: Mechanisms of B Cell Responses in Autoimmune Disease: C12-ASC01-UMI
Sponsor: NIH - Subcontracts TO Duke University U19 AI 056363
Project Dates and Amount of Award: 05/01/12-04/30/13; $173,020
Co-I: Gillespie, Brenda (Ctr Statistical Consul & Res)
Title: Novel Control Group to Expand the Scope of the RELIVE Living Kidney Donor Study
Sponsor: NIH - Subcontracts TO Arbor Research Collaborative For Health R21 DK 097493
Project Dates and Amount of Award: 09/27/12-08/31/13; $10,363
Title: Nras Signaling in Hematopoietic Stem Cells and Leukemic Stem Cells
Sponsor: V Fdn for Cancer Research, The
Project Dates and Amount of Award: 11/01/12-10/31/14; $200,000
Title: A Phase 2 Double-blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics and Safety of LCP-Tacro(tm) Tablets, Once-daily, Compared to Prograf(R) Capsules, Twice-daily, in Combination with Mycophenolate Mofetil for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Sponsor: Veloxis Pharmaceuticals TO ICON Clinical Research, Inc.
Project Dates and Amount of Award: 02/04/13-02/03/14; $64,285
Awardee / Fellow: Harder-Krans, Jennifer
Title: Genesis of Epithelial Cell Lumens
Sponsor: NIH 1 K08 DK 089119 01 A1
Project Dates and Amount of Award: 01/15/13-11/30/17; $776,012
Title: ACR REF/Amgen Rheumatology Fellowship Training Award 2012
Sponsor: Amer College of Rheumatology
Project Dates and Amount of Award: 07/01/13-06/30/14; $25,000
Title: Using complex systems approaches to facilitate the discovery of next generation anti-cancer strategies
Sponsor: McDonnell, James S., Fdn
Project Dates and Amount of Award: 03/01/13-02/28/15; $200,000
Co-I: Galecki, Andrzej (IntMed-Geri & Palliative Med.)
Title: Novel Biomarkers and ImmunoChip Analysis in Type 1 Diabetes
Sponsor: Juvenile Diabetes Research Foundation International (JDRF)
Project Dates and Amount of Award: 01/01/13-12/31/13; $82,000
Awardee / Fellow: Patel, Dipak
Title: PP5 is a Novel Epigenetic Regulator in Lupus T Cells
Sponsor: Amer College of Rheumatology
Project Dates and Amount of Award: 07/01/13-06/30/15; $125,000
Title: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
Sponsor: Millennium Pharm, Inc. TO PPD, Inc.
Project Dates and Amount of Award: 01/18/13-01/19/20; $449,025
Title: A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis: UMCC 2012.100
Project Dates and Amount of Award: 12/14/12-11/30/16; $709,776
Co-I: Bai, Longchuan (Int Med-Hematology/Oncology)
Title: Cell Death Activation to Prevent Late Relapse in Breast Cancer
Sponsor: Susan G. Komen for the Cure TO Washington University
Project Dates and Amount of Award: 10/09/12-10/08/13; $153,670
Awardee / Fellow: Ma, Teng
Title: The Analysis of NEDD8-activating Enzyme Inhibitor MLN4924 on Ovarian Cancer
Sponsor: Ovarian Cancer Research Fund, Inc., The (OCRF)
Project Dates and Amount of Award: 03/01/13-02/28/14; $75,000
Co-I: Baker, Laurence (Int Med-Hematology/Oncology) / Meng, Fan (Psychiatry Department)
Title: SARC Sarcoma SPORE
Sponsor: NIH - Subcontracts TO SARC
Project Dates and Amount of Award: 09/26/12-08/31/13; $224,551
Microbiology and Immunology
Title: Subversion of Gastrointestinal Host Defenses by Norovirus
Sponsor: NIH 1 R21 AI 103961 01 A1
Project Dates and Amount of Award: 01/15/13-12/31/14; $427,741
Title: The Impact of the Metabolic Syndrome on Neuropathy
Sponsor: NIH 1 K23 NS 079417 01
Project Dates and Amount of Award: 07/01/13-06/30/18; $936,900
Title: Continuation of NET-PD Trials at the University of Michigan
Sponsor: NIH 2 U10 NS 044504 11
Project Dates and Amount of Award: 01/01/13-11/30/15; $179,359
Title: 2012-2013 Neuroimmunology Lecture Series
Sponsor: Teva Neuroscience
Project Dates and Amount of Award: 11/01/12-12/31/13; $52,104
Awardee / Fellow: He, Fang
Title: Determination of the Toxic Species in Fragile X-associated Tremor Ataxia Syndrome
Sponsor: National Ataxia Foundation
Project Dates and Amount of Award: 01/01/13-12/31/13; $35,000
Title: Stroke Hyperglycemia Insulin Network Effort
Sponsor: NIH - Subcontracts TO Henry Ford Hospital
Project Dates and Amount of Award: 01/01/13-08/31/13; $136,000
Title: A non-randomized, open-label dose-finding trial of combined cytotoxic and immune stimulatory strategy for the treatment of resectable primary malignant glioma
Sponsor: Phase ONE
Project Dates and Amount of Award: 01/01/13-12/31/15; $216,000
Co-I: Castro, Maria (Neurosurgery)
Title: Mechanisms of Glioma Growth and Invasion Novel Therapeutic Strategies
Sponsor: NIH 1 R01 NS 082311 01
Project Dates and Amount of Award: 04/01/13-03/31/18; $1,700,780
Obstetrics & Gynecology
Co-I: Engleberg, N (Int Med-Infectious Diseases) / Moyer, Cheryl (Med Ed/Ofc of Ed Resources&Res)
Title: OBGYN Residency Training Program: A University of Michigan and St. Paul Millennium Medical College Collaboration
Sponsor: HRSA TO American International Health Alliance, Inc.
Project Dates and Amount of Award: 12/01/12-09/30/13; $276,079
Ophthalmology & Visual Sciences
Title: Bone Marrow Neuropathy Drives Diabetic Retinopathy
Sponsor: NIH - Subcontracts TO University Of Florida
Project Dates and Amount of Award: 09/30/12-08/31/16; $435,848
Title: RPB Unrestricted Grant 2012
Sponsor: Research To Prevent Blindness
Project Dates and Amount of Award: 01/01/13-12/31/13; $110,000
Title: Characterization of a SCID-HDM model
Sponsor: Janssen Pharmaceutica, Inc.
Project Dates and Amount of Award: 09/01/12-12/31/13; $200,805
Title: Mechanistic Studies about Producing Host Defense Factors Against Yersinia and Evaluating their Antimicrobial Effect
Sponsor: South Korea, Government of TO Konyang University
Project Dates and Amount of Award: 09/01/12-08/31/15; $176,575
Pediatrics & Communicable Diseases
Title: Public Health Surveillance and Follow-up of Patients with Sickle Cell Diseases in the State of Michigan
Sponsor: CDC-Subcontracts TO MI, State Of Community Health U50
Project Dates and Amount of Award: 11/01/12-09/30/13; $28,400
Title: Coordinate Regulation of Competence and Pneumocin Production in S. pneumoniae
Sponsor: NIH 1 R01 AI 101285 01 A1
Project Dates and Amount of Award: 02/05/13-01/31/18; $1,706,053
Co-I: Chugh, Rashmi (Int Med-Hematology/Oncology) / Thomas, Dafydd (Pathology Department)
Title: SARC Sarcoma SPORE
Sponsor: NIH - Subcontracts TO SARC U54 CA 168512
Project Dates and Amount of Award: 09/26/12-08/31/13; $299,218
Title: Study Chair: NIH COG Chair Grant (U10CA098543)
Sponsor: NIH - Subcontracts TO Children's Hospital of Philadelphia, The
Project Dates and Amount of Award: 01/01/13-12/31/13; $15,000
Title: A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation Study
Sponsor: Vertex Pharmaceuticals
Project Dates and Amount of Award: 01/17/13-11/29/15; $122,026
Title: Study Chair Yanik: NIH COG Chair Grant (U10CA098543) ASCT0521
Sponsor: NIH - Subcontracts TO Children's Hospital of Philadelphia, The
Project Dates and Amount of Award: 01/01/13-12/31/13; $7,500
Title: High-Resolution Multi-color FLIM-FRET Imaging of Whole Organism
Sponsor: NIH - Subcontracts TO University of Arizona R01 EB 015481
Project Dates and Amount of Award: 08/01/12-05/31/13; $7,775
Awardee / Fellow: Auerbach, David
Title: Sudden Cardiac Death in a Severe Form of Childhood Epilepsy: Mice & Men
Sponsor: Epilepsy Foundation of America
Project Dates and Amount of Award: 01/01/13-12/31/13; $45,000
Title: Effects of experimental compounds measured by various assays in monkeys
Sponsor: Sunovion Pharmaceuticals Inc
Project Dates and Amount of Award: 02/07/13-01/31/14; $184,500
Title: Psychiatric Consulting - Fee for Services Project
Sponsor: MI, State Of Community Health
Project Dates and Amount of Award: 11/01/12-09/30/13; $169,949
PI: *Ewell Foster,Cynthia
Title: Caring Calls: A Supportive Intervention for Families of Suicidal Youth
Sponsor: Macomb, County of
Project Dates and Amount of Award: 11/01/12-09/30/13; $9,654
Title: Implementation of Integrated Measurement-based Care for Persons with Serious Mental Illness
Sponsor: Genesee County
Project Dates and Amount of Award: 11/01/12-09/30/13; $3,698
Title: Facilitating Implementation of Programs to Promote Recovery Among Consumers with SMI
Sponsor: Washtenaw Community Health Organization
Project Dates and Amount of Award: 10/01/12-09/30/13; $44,939
Co-I: Hua, Liwei (Psychiatry Department)
Title: Increasing Mental Health Treatment Access for Underserved Children and Adolescents
Sponsor: Flinn, Ethel and James, Foundation
Project Dates and Amount of Award: 01/01/13-12/31/14; $200,000
Title: Predictors of Response to Perinatal Depression Treatment: Establishing Processes and Infrastructure for Multisite Effectiveness Research
Sponsor: AHRQ - Subcontracts TO Florida State University R03 HS 020987
Project Dates and Amount of Award: 10/02/11-09/29/13; $23,972
Co-I: Maixner, Daniel (Psychiatry Department) / Mickey, Brian (Psychiatry Department)
Title: C-07-05: A Long-Term Follow Up Study for the Evaluation of Patients Who Have a Deep Brain Stimulation System for the Adjunctive Treatment of Major Depressive Disorder
Sponsor: St. Jude Medical, Inc.
Project Dates and Amount of Award: 01/16/13-02/28/17; $294,915
Co-I: Eisenberg, Daniel (Health Management and Policy)
Title: A Peer-to-Peer Program on College Campuses to Improve Wellbeing and Mental Health Outcomes of Student Veterans
Sponsor: Bristol-Myers Squibb Foundatio
Project Dates and Amount of Award: 11/01/12-11/30/15; $916,003
Awardee / Fellow: Weiland, Barbara
Title: The Role of Dopaminergic Reward Circuitry in Substance Abuse Risk
Sponsor: Brain and Behavior Research Foundation
Project Dates and Amount of Award: 01/15/13-01/14/15; $60,000
Co-I: Greenson, Joel (Pathology Department)
Title: Anti-pancreatic Tumorigenesis by Inactivation of SAG/RBX2 E3 Ubiquitin Ligase
Sponsor: NIH 1 R21 CA 170995 01 A1
Project Dates and Amount of Award: 01/01/13-12/31/14; $321,302
Title: ACRIN Patient Centered Outcomes and Survivorship Committee Co-Chair
Sponsor: NIH - Subcontracts TO American College of Radiology U10 CA 037403
Project Dates and Amount of Award: 09/26/12-05/31/13; $17,000
Co-I: Goldstein, Steven (Orthopaedic Surgery)
Title: Translational Optimization of Bone Regeneration in the Irradiated Mandible
Sponsor: NIH 2 R01 CA 125187 06 A1
Project Dates and Amount of Award: 12/05/12-11/30/17; $1,101,331
Title: The ROADSTER Plus Study-INVESTIGATION of FLOW ALTERED, SHORT TRANSCERVICAL CAROTID ARTERY STENTING in PATIENTS with SIGNIFICANT CAROTID ARTERY DISEASE with filter
Sponsor: Silk Road Medical, Inc
Project Dates and Amount of Award: 01/15/13-11/30/16; $96,000
Title: Training for Front End Innovation in Surgical Tools
Sponsor: Covidien Surgical Devices
Project Dates and Amount of Award: 01/25/13-09/30/13; $200,000
Title: Topical Nanoemulsion Therapy for Burn Wounds
Sponsor: NanoBio Corporation
Project Dates and Amount of Award: 12/15/12-11/30/13; $40,000
Title: Liu Lab Operations
Sponsor: Children's Research Institute
Project Dates and Amount of Award: 10/01/12-06/30/13; $250,000
Title: Effect of DI17E6 in Preclinical Prostate Cancer Models
Sponsor: Merck, Inc
Project Dates and Amount of Award: 12/21/12-12/20/13; $31,100
Title: Correlation of Non-DRE, Urine Exosome Gene Signatures with Prostate Cancer Detection and Clinical Outcome at Prostatectomy
Sponsor: Exosome Diagnostics, Inc.
Project Dates and Amount of Award: 01/04/13-01/03/14; $160,000
Title: Correlation of Non-DRE, Urine Exosome Gene Signatures with the Results of a Prostate Needle Biopsy
Sponsor: Exosome Diagnostics, Inc.
Project Dates and Amount of Award: 01/04/13-01/03/14; $160,000
Books – Chapters or Volumes of Books – Contributions to Books
Albin RL. Parkinson’s Disease and Sleep. In: Kushida CA (ed.) The Encyclopedia of Sleep, Waltham, MA: Academic Press, vol. 4, pp. 345-349, 2013.
The list of research journal articles will continue in the next issue of UMMS Research News.
For more information about what’s going on across the UM Medical Campus:
- Health System Headlines connects you to what's happening daily throughout the Medical School, the Health System and the University.
- UMHS Newsroom lists breaking news from the Health System.
Media inquiries about research at the UMMS? CLICK HERE